To further elucidate the role of PKA and STAT3 in the CaSR-claudin-14 pathway, we treated a rat model of ethylene glycol-induced kidney stones by co-administering the CaSR activator R568 along with the PKA inhibitor or the STAT3 inhibitor. The gene discussed is CLDN14; the disease is nephrolithiasis.